Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses
Dexmedetomidine is correlated with reduced in-hospital mortality in aSAH, potentially by regulating AR and immune pathways. These findings highlight AR as a promising therapeutic target of dexmedetomidine for aSAH management.
Authors
- Zhiang Li (ORCID: https://orcid.org/0000-0001-9289-9516)
- Lihong Hu (ORCID: https://orcid.org/0000-0001-5138-3660)
- Hongcai Wang (ORCID: https://orcid.org/0000-0002-3343-7853)
- Xuewei Zhang (ORCID: https://orcid.org/0000-0003-4516-575X)
Institutions
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.3389/fneur.2025.1554809
- Primary Topic
- Intracranial Aneurysms: Treatment and Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00